Author Topic: Results of Phase I trial of CPHPC + anti-SAP antibodies  (Read 18507 times)

Miriam Vered

  • Administrator
  • *****
  • Posts: 560
Results of Phase I trial of CPHPC + anti-SAP antibodies
« on: April 05, 2015, 07:19:38 am »
Hi All,

The attached abstract was presented at the Annual Meeting of the Association of Physicians 27 March 2015.

Below is Professor Sir Mark Pepys' explanation:

The abstract summarises the findings of the initial part of the Phase I trial of the obligate therapeutic partnership of CPHPC plus anti-SAP antibodies in patients with systemic amyloidosis.

This was the first in human clinical trial of a first in class treatment that has never been used before.  The main aim was to show that the drug combination is safe and acceptably tolerated in patients.

Patients with amyloid in the heart were excluded from this first part of the trial for safety reasons.  We have substantial experience with CPHPC in amyloid patients and it has always been absolutely safe but anti-SAP antibodies have not previously been given.  The initial antibody doses were accordingly very small but in the absence of any ill effects, larger doses were given and were generally well tolerated.

Most of the patients were selected because they had amyloid affecting the liver as well as some other organs.  There are several different powerful methods for assessing both liver amyloid load and liver function.

The important results of the trial so far are as follows:

1.  The treatment is safe and well tolerated.

2.  After treatment with a sufficient antibody dose, there was evidence of reduction in amyloid load in almost all subjects.  This was associated with improved liver function in some subjects.

This finding is unprecedented.

There has never been any other treatment that directly targets amyloid deposits nor any intervention which produces such rapid clearance of amyloid from the tissues.

In some individuals the disappearance of amyloid was dramatic and in others, with much larger initial amyloid load, it was more subtle.  Crucially the dose level at which amyloid clearance was seen was much smaller than the optimal dose used in the mouse experiments on which this new clinical treatment was based.  Further experience with larger and repeated antibody doses, not yet reported, shows that additional clearance from the liver and other organs can be achieved.

The present trial is continuing and plans for a Phase II trial, aiming to confirm clinical efficacy and patient benefit are in progress.  However the results so far have shown convincingly that reduction in amyloid load in the tissues leads to improved organ function.

Peter

  • *
  • Posts: 6
  • Reason for joining: Patient
  • Diagnosed: March 2013
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #1 on: April 05, 2015, 08:46:41 am »
Miriam
The results look very encouraging, I heard about the drug when I was last at the NAC in November of last year, due up again early next month. I asked then no doubt like many others if I could be included on the trials but because of the heart involvement was told no as explained in your post.
What are the chances of this being extended seeing the positive results received, ever hopefull

patpinchin

  • *****
  • Posts: 603
  • AL - extensive in skin. mouth + palatal nerves '04
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #2 on: April 05, 2015, 09:12:51 am »
Hurrah! Happy Easter everyone!  :) :) :)
Such wonderful news and so eagerly awaited by so many.
The best Easter Egg for Amyloidosis sufferers in the UK.

Congratulations and huge thanks to Professor Sir Mark Pepys and his team after so many years of hard work.   :)  :):)

Onwards and upwards with phase 2.

Thank-you SO much Miriam for posting this.  :) :) :)
« Last Edit: April 05, 2015, 10:06:07 am by patpinchin »
Pat

Annone Butler

  • *
  • Posts: 22
  • Reason for joining: Husband diagnosed with AL Cardiac Amyloidosis in 2010
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #3 on: April 05, 2015, 12:22:33 pm »
Very good news. And just in time for Spring! Many Congratulations to all the team at the NAC and GSK.

Elliei21@me.com

  • *
  • Posts: 35
  • Reason for joining: A patient
  • Diagnosed: July 2010
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #4 on: April 05, 2015, 05:12:13 pm »
Thankyou Miriam for this most promising post on Easter Sunday, the results are very encouraging and hopeful for so many of us reading these results, I am at the NAC early May, I will definitely be asking about these trials whilst I'm there too.
I think we can all agree that there is a lot of hope for Amyloidosis sufferers when we are receiving trial results like that.
Great news !!!!! EllieX

Helen33

  • *
  • Posts: 21
  • AL Amyloidosis in kidneys, bones and spleen
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #5 on: April 05, 2015, 05:39:40 pm »
I do hope that I might be considered for  this trial drug.  Can someone inform me who I need to approach please.  It seems so much better option for me than more chemotherapy to try to prevent my kidneys going further into decline.  It is highly probable that the chemotherapy causes more damage. 

What a magnificent breakthrough. 
Living life with Amyloidosis

patpinchin

  • *****
  • Posts: 603
  • AL - extensive in skin. mouth + palatal nerves '04
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #6 on: April 05, 2015, 06:35:01 pm »
I am among the small number of NAC patients awaiting this news for many years. Dr Gilmore first told me about CPHPC and its testing on mice models in 2006. It took several more years before the anti-SAP antibody was on the agenda. Eventually the reality of a drug and the leading drug company GSK to sponsor clinical trials costing many billions of pounds. Now 9 years later we have received today's amazing news from the wonderful great man who invented the drug. Proof of safety of the drug in humans, evidence of clearance of amyloid even at low dose at rates according to load and a phase 2 trial to prove efficacy in plan. In addition, one of the first new drugs designated by the European Medical Agency for fast tracking. Professor Pepys has devoted his life to Amyloidosis since he established the NAC all those years ago. Although sadly this drug is too late for some, current NAC patients can be hopeful of a better quality of life to come. We are indeed indebted to Sir Mark and his NAC team of researchers and Doctors.
Pat

Miriam Vered

  • Administrator
  • *****
  • Posts: 560
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #7 on: April 05, 2015, 08:19:23 pm »

Helen asked:

Quote
I do hope that I might be considered for  this trial drug.  Can someone inform me who I need to approach please.


I'm sure that everyone on the forum is thinking something similar.


This is Professor Sir Mark Pepys' answer:


The entry criteria for the trial are extremely stringent for safety reasons. All patients under the care of the NAC are well known to those involved in selecting trial candidates and will be approached appropriately when the time is right. Please be assured that we are well aware of the desire of all patients to receive useful treatment as soon as possible and we are doing our best to ensure that this happens. Our goal is to create a safe new medicine that will benefit patients and everybody involved is working as hard as they can to make this happen as early as possible.



Elizabeth

  • *
  • Posts: 3
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #8 on: April 05, 2015, 09:13:41 pm »
This sounds wonderful news and I'm sure gives all amyloidosis sufferers greater hope for the future. Many thanks for all involved in the research and development of this drug, as this could possibly transform the lives of many such as myself who suffer the consequences of this disease, and hopefully give us a far better prognosis.

JellybabyJan

  • *
  • Posts: 16
  • Reason for joining: Husband Mike has AL Amyloidosis in Heart, Kidney's, Liver;Spleen and nervous system
  • Diagnosed: Apr 2013
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #9 on: April 06, 2015, 05:11:37 pm »
Hi Miriam

Great news.  Do you know if it will ever be available for patients with cardiac amyloidosis? I think it's worth the risk. Thanks.

Jan x

Miriam Vered

  • Administrator
  • *****
  • Posts: 560
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #10 on: April 06, 2015, 07:15:08 pm »
Hi Jan,


The treatment is being developed with a goal of treating all types of amyloidosis affecting all organs, including cardiac amyloidosis. Unfortunately we don't yet know how effective it will be, and how long it will take until it is more widely available.
The information above is all that I can provide right now.
 I'll keep you all posted when further information is available.
 
« Last Edit: April 06, 2015, 07:17:06 pm by Miriam Vered »

Lesley

  • ***
  • Posts: 177
  • Reason for joining: Amyloid patient (AL)
  • Diagnosed: December 2012
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #11 on: April 06, 2015, 07:39:07 pm »
If I had to give up one thing.... Mine wd be that pat Pinchin takes this drug trial before me. This wonderful courageous lady deserves  a hope. Please let pat be the one to trial this drug. My love to a very special brave lovely lady - pat Pinchin xxxx

patpinchin

  • *****
  • Posts: 603
  • AL - extensive in skin. mouth + palatal nerves '04
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #12 on: April 06, 2015, 07:54:07 pm »
Please can you confirm Miriam, that the potential of the new drug is to clear amyloid deposits in tissues as well as organs? Organ involvement does not affect all AL sufferers, and is as you know very hard to treat when soft tissue is the area involved. Amyloid has thus far rarely regressed from soft tissue even with a full or very good haematological response.
Pat

JellybabyJan

  • *
  • Posts: 16
  • Reason for joining: Husband Mike has AL Amyloidosis in Heart, Kidney's, Liver;Spleen and nervous system
  • Diagnosed: Apr 2013
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #13 on: April 06, 2015, 07:56:45 pm »
Hi Miriam

Thanks for the update, still very exciting

Jan

Miriam Vered

  • Administrator
  • *****
  • Posts: 560
Re: Results of Phase I trial of CPHPC + anti-SAP antibodies
« Reply #14 on: April 07, 2015, 07:34:13 am »
Pat asked:
Quote
Please can you confirm Miriam, that the potential of the new drug is to clear amyloid deposits in tissues as well as organs? Organ involvement does not affect all AL sufferers, and is as you know very hard to treat when soft tissue is the area involved. Amyloid has thus far rarely regressed from soft tissue even with a full or very good haematological response.


Hi Pat,


Professor Sir Mark Pepys' reply is as follows:


The aim of the treatment is to remove all systemic amyloid deposits from all tissues and organs. There are no animal models suited for investigation of this potential and only continuing clinical testing will eventually reveal the full effectiveness of the intervention. Initially the testing can only proceed in the context of a formal clinical trial with its unavoidably restrictive and onerous regulatory framework. Provided there are no safety issues and the results continue to be encouraging, it is possible that inclusion criteria may be broadened and that eventually there might be a possibility of compassionate use. However this is very uncertain and will be decided by GSK and not by the NAC, although we shall certainly suggest and advise.